Saudi Arabia Cancer Immunotherapy Market Size & Outlook
Saudi Arabia cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Saudi Arabia cancer immunotherapy market highlights
- The Saudi Arabia cancer immunotherapy market generated a revenue of USD 492.7 million in 2023 and is expected to reach USD 819.4 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 492.7 million |
| Market revenue in 2030 | USD 819.4 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.4% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 103.7 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.43% in 2023. Horizon Databook has segmented the Saudi Arabia cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer is the leading cause of mortality in Saudi Arabia, which also records a high disease prevalence. There were nearly 24,485 cancer incidence in the country in 2018. The highest cancer malignancies were recorded in breast, colorectal, thyroid, and leukemia. High consumer awareness about cancer and wide-scale adoption of cancer immunotherapy are high impact-rendering factors of market growth in the country.
Oncologists in Saudi Arabia reported that cancer patients were more responsive toward cancer immunotherapy than traditional chemotherapeutic regimens. Furthermore, the Saudi Oncology Health Economics Expert Group (SHARP) was set up by AstraZeneca and the Saudi Society of Clinical Pharmacy (SSCP) to analyze treatment costs and create a cost-effective platform for cancer patients.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia cancer immunotherapy market size, by product, 2018-2030 (US$M)
Saudi Arabia Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
